Fertility Startup Gameto Raises $44 Million to Test Egg-Freezing Therapy in US

Gameto Inc., a fertility startup, has raised $44 million in venture capital to fund a clinical trial for its egg-freezing therapy in the United States. The company is developing stem-cell-based treatments to enhance the egg-freezing process, which can be an important option for women who want to preserve their fertility. The funding will allow Gameto to test its proprietary technology, which aims to improve the success rate and experience of egg freezing. The company's approach focuses on improving the quality and viability of frozen eggs, a critical factor in the effectiveness of fertility treatments. The successful fundraising round underscores the growing demand for innovative solutions in the women's health and fertility space. Gameto's technology has the potential to make the egg-freezing process more accessible and effective for women who wish to preserve their fertility options for the future.